Want to see TARS full AI Analyst Report?
TARS Stock Chart & Stats
$67.24
$0.07(0.13%)
At close: 4:00 PM EST
$67.24
$0.07(0.13%)
Day’s Range― - ―
52-Week Range$38.51 - $85.25
Previous CloseN/A
Volume127.14K
Average Volume (3M)1.11M
Market Cap
$2.57B
Enterprise Value$2.71K
Total Cash (Recent Filing)$388.73M
Total Debt (Recent Filing)$88.68M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Aug 06, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding43,023,960
10 Day Avg. Volume1,600,524
30 Day Avg. Volume1,107,531
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)9.96
Price to Sales (P/S)7.58
P/FCF Ratio-153.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$94.63Price Target Upside40.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$701.16M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 90% indicate very strong product-level economics for XDEMVY/XTENVI. High product margins provide durable capacity to fund commercial scale and R&D, absorb gross-to-net variability, and support profitability as volumes grow over the next several quarters.
Commercial Momentum And AdoptionRapid top-line growth and meaningful prescriber adoption signal durable demand establishment rather than a fleeting spike. Expanding ECP weekly prescribers and stronger DTC engagement expand the patient funnel and recurring prescriptions, underpinning sustainable revenue growth over the coming 2–6 months.
Manageable Leverage / Balance SheetA relatively conservative leverage profile gives the company flexibility to invest in commercialization, complete pipeline programs, or absorb near-term shocks without acute solvency risk. This financial runway supports multi-quarter execution and optionality on partnering or bolt-on deals.
Bears Say
Negative Operating And Free Cash FlowPersistent cash burn, despite improvement, means the business is not yet self-funding; this constrains organic investment and forces reliance on external capital, partnerships, or milestone receipts. Cash consumption is a structural constraint on growth and capital allocation over the next several quarters.
Ongoing Net Losses And Negative ReturnsContinuing net losses and negative ROE indicate the company has not converted strong unit economics into bottom-line profitability. Until operating leverage and SG&A/R&D efficiency improve, losses will limit retained earnings and may pressure strategic choices around investment, partnerships, or cost control.
Pipeline Execution / Partner DependencyKey late-stage programs (e.g., TPO5) require large Phase III commitment and probable partnering, adding execution and counterparty risk. Reliance on external partners for pivotal trials or commercialization creates timing, milestone dependency, and dilution risks that affect diversification plans over the medium term.
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals, Inc.’s price range in the past 12 months?
Tarsus Pharmaceuticals, Inc. lowest stock price was $38.51 and its highest was $85.25 in the past 12 months.
What is Tarsus Pharmaceuticals, Inc.’s market cap?
Tarsus Pharmaceuticals, Inc.’s market cap is $2.57B.
When is Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date?
Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Tarsus Pharmaceuticals, Inc.’s earnings last quarter?
Tarsus Pharmaceuticals, Inc. released its earnings results on May 06, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.4 by $0.24.
Is Tarsus Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Tarsus Pharmaceuticals, Inc. pay dividends?
Tarsus Pharmaceuticals, Inc. does not currently pay dividends.
What is Tarsus Pharmaceuticals, Inc.’s EPS estimate?
Tarsus Pharmaceuticals, Inc.’s EPS estimate is -0.17.
How many shares outstanding does Tarsus Pharmaceuticals, Inc. have?
Tarsus Pharmaceuticals, Inc. has 43,023,960 shares outstanding.
What happened to Tarsus Pharmaceuticals, Inc.’s price movement after its last earnings report?
Tarsus Pharmaceuticals, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.4. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in TARS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tarsus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$94.63 (40.73% Upside)
$94.63 (40.73% Upside)
Blogger Sentiment
Neutral
TARS Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 245.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.05%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
TARS Stock 12 Month Forecast
Average Price Target
$94.63
▲(40.73% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
3.26% Insiders
21.54% Mutual Funds
3.30% Other Institutional Investors
59.30% Public Companies and
Individual Investors